Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Fund moves › Immunic › OrbiMed Advisors LLC cut its IMUX stake below 5% (2.3%) Fund moves
Why it stands out The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Date of the event that required the filing Sep 30, 2026
Reporting period Not applicable
Filed with the SEC Nov 16, 2026 passive 5% holder
Context Change vs prior quarter Undefined
Compared with the manager's prior 13F
Tracked managers with the same change NaN
For the same quarter
0000947871-26-001032
Data quality Verified: identifiers matched exactly
Around the same time Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Aug 6, 2026 Company filing · Form 8-K · Results, Executive change Changed a top executive or board member, and reported its results (and 1 more item) “On August 6, 2026, the board of directors (the “Board”) of the Company appointed Elena Ridloff as a member of the Board, effective immediately. As a Class I director, Ms. Ridloff’s term lasts until the Company’s 2027 annual meeting of stockholders, and until her successor is duly elected and qualified, or until her earlier death, resignation or removal.” Sep 10, 2026 Company filing · Form 8-K · Executive change Changed a top executive or board member “On September 10, 2026, Dr. Duane Nash resigned as a member of the Board of Directors (the “Board”) of Immunic, Inc., a Delaware corporation (the “Company”). Dr. Nash’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.” What came next Nov 2, 2026 5% stake Aberdeen Group plc reported a passive stake (13G) of 8.0% Nov 13, 2026 Company filing · Form 8-K · Results Reported its results Nov 13, 2026 5% stake Morgan Stanley reported a passive stake (13G) of 5.2% Nov 16, 2026 5% stake OrbiMed Advisors LLC reported a passive stake (13G) of 2.3%